Stifel Financial Corp Takes $544,000 Position in Alto Neuroscience, Inc. (NYSE:ANRO)

Stifel Financial Corp acquired a new position in Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 128,700 shares of the company's stock, valued at approximately $544,000. Stifel Financial Corp owned approximately 0.48% of Alto Neuroscience at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the business. Franklin Resources Inc. grew its holdings in shares of Alto Neuroscience by 95.3% in the 3rd quarter. Franklin Resources Inc. now owns 1,220,712 shares of the company's stock worth $13,965,000 after acquiring an additional 595,673 shares during the last quarter. Jane Street Group LLC acquired a new stake in Alto Neuroscience in the third quarter valued at approximately $124,000. JPMorgan Chase & Co. raised its holdings in Alto Neuroscience by 543.4% during the third quarter. JPMorgan Chase & Co. now owns 24,315 shares of the company's stock valued at $278,000 after buying an additional 20,536 shares in the last quarter. Rhumbline Advisers boosted its position in Alto Neuroscience by 24.4% during the fourth quarter. Rhumbline Advisers now owns 25,556 shares of the company's stock worth $108,000 after purchasing an additional 5,008 shares during the period. Finally, Wellington Management Group LLP raised its holdings in Alto Neuroscience by 27.2% in the 4th quarter. Wellington Management Group LLP now owns 77,146 shares of the company's stock worth $326,000 after acquiring an additional 16,510 shares during the period.

Alto Neuroscience Trading Up 6.8%

ANRO stock traded up $0.15 during midday trading on Thursday, reaching $2.35. The stock had a trading volume of 92,742 shares, compared to its average volume of 381,830. The company has a quick ratio of 13.09, a current ratio of 13.10 and a debt-to-equity ratio of 0.05. Alto Neuroscience, Inc. has a twelve month low of $1.60 and a twelve month high of $17.55. The firm has a market cap of $63.62 million, a price-to-earnings ratio of -0.93 and a beta of 1.87. The business has a fifty day simple moving average of $2.41 and a two-hundred day simple moving average of $3.46.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.06. As a group, research analysts expect that Alto Neuroscience, Inc. will post -2.54 EPS for the current fiscal year.

Analyst Ratings Changes

ANRO has been the subject of a number of research analyst reports. Wedbush reiterated a "neutral" rating and set a $4.00 price target on shares of Alto Neuroscience in a report on Thursday. HC Wainwright began coverage on Alto Neuroscience in a research report on Monday, April 7th. They set a "buy" rating and a $10.00 target price for the company. Finally, William Blair reaffirmed an "outperform" rating on shares of Alto Neuroscience in a research note on Friday, March 21st. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $15.40.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.